Medical Treatment of Down Syndrome and Genetic Diseases

412 Pages·1985·51.26 MB·English

by  Henry Turkel

•
•
Henry Turkel, M.A., M.D.
lise Nusbaum, M.A.
$12.00
•
ABOUT
THEAUIHOR
HENRY TURKEL, M.D., was
born in Austria in 1903 and came
to the United States in 1923. He
received a B.A. in Chemistry from
Ohio State University and an
M.A. in Anatomy and M.D. from
the University of Michigan. He is
licensed to practice medicine in
Michigan, Ohio, and the District
of Columbia.
He invented the Turkel Trephine Instruments for bone
marrow infusion and tissue biopsies. During World War II and
thereafter, this instrument was adopted by the U.S. Armed Forces
and has saved many thousands of lives. They are mentioned m
scientific papers by some 800 different authors and in some 350
textbooks in more than ten different languages. He has been
mentioned in the International Who's Who in the World of
Medicine and the World Who's Who among numerous other
publications . He has received many international honors for his
work. He is a member of the Academy of Orthomolecular
Psychiatry, American Association for the Advancement of
Science, American Association on Mental Deficiency,
International Society of Hematology, Southern Medical
Association, and many other professional organizations, and is a
life member of the American Medical Association, Royal Society
of Medicine, and Association of Military Surgeons.
He has lectured about Down syndrome and inborn errors of
metabolism at many medical conventions around the world,
including the American Academy of General Practice, the
Philosophical Society of England, the International Congress of
Genetics in Holland, the Second International Congress on
Mental Retardation in Vienna, and many others.
Dr. Turkel Lives and practices medicine in Southfield,
Michigan. He and his wife have five grown children.
UBIOTICA/19145 W. NINE MILE ROAD/SOUTHFIELD, M148075
•
MEDICAL TREATMENT OF
DOWN
SYNDROME
AND GENETIC DISEASES
MEDICAL TREATMENT OF
AND GENETIC DISEASES
.
Henry Turkel, M.A., M.D.
lise Nusbaum, M.A.
CHAPTERS BY
LINUS PAULING, PH.D.
BERNARD RIMLAND, PH.D.
ROBERT J. DOMAN, M.D.
I. KURITA, M.D.
Fourth Revised Edition
UBIOTICA/SOUTHFIELD, MICHIGAN
Copyright © 1985 Henry Turkel and lise Nusbaum
All rights reserved. No part of this book may be reproduced or transmitted in any
form or by any means, electronic or mechanical, without written permission.
Library of Congress
Catalog Card Number: 85-51388
ISBN: 0-4615119-0-7
l. Mental Retardation. 2. Down Syndrome. 3. Medical Treatment of Cyto
genetic Diseases. 4. Components of the "U" Series. 5. Patient Reports and Case
Histories. 6. Regression of Cataracts in Down Syndrome. 7. Prevention of I.Q.
decline in Down Syndrome. 8. lntellectuallmprovement with "U" Series.
Published by UBIOTICA
19145 West Nine Mile Road
Southfield, Ml 48075
Manufactured in the United States of America
ACKNOWLEDGMENTS
With gratitude to all who have encouraged
me -in my work with Down syndrome patients, I
give special thanks to Dr. Linus Pauling, who
wrote the Introduction, Dr. Bernard Rimland,
whose 1976 Foreword to New Hope - UPDATE has
been reprinted in this book, Dr. Robert J. Doman
who contributed a chapter, and the many other
colleagues: Dr. Robert Mendelsohn, Dr. Carlton
Fredericks, Mr. Robert Doman, Jr., Director of
the National Association of Child Development,
Dr. Glenn Doman and the staff of the Institutes
for the Achievement of Human Potential, Dr.
Abram Hoffer and other colleagues of the Academy
of Orthomolecular Psychiatry, Dr. Jacob Siegel,
Dr. Ruth Harrell, Dr. Jack Warner, and Dr. A.
Rosanova.
Friends and colleagues abroad - Dr. M.
Iida, Dr. I. Kurita, Dr. T. Koishi of Japan, and
physicians and parents in Norway, especially Dr.
Terje Sandstrak, Dr. K.L. Reichelt, Mrs. Phyllis
Nyquist, and Mrs. Lita Heiding - have made it
possible for Down syndrome children to receive
the "U" Series in their own countries.
I am also grateful to Mr. Robert Rodale and
the staffs of Prevention and Let's Live
magazines, to Dr. Betty Lee Morales, and the
many other journalists who have informed parents
and doctors about treatment.
I thank my family, especially my wife,
Jeanne, full partner in all my work, and my
daughter, Ellen Kallick, for her expert editing
of the manuscript; I also thank my secretary,
Betty A. Block, my medical assistant, Margaret
Nusbaum, and the patients' parents, especially
Herman and Arline Burman and Sam and June Maglio
of US for DS, whose . assistance in the
publication of the 1976 and 1980 revisions of
New Hope for the Mentally Retarded and the
present book has been invaluable.
v
CONTENTS
PART I
MEDICAL OF DOWN SYNDROME
TREATMENT
Acknowledgements v
Introductory Chapter, L. Pauling, Ph.D. 1
Author's Statement 3
Commentary, 1976, B. Rimland, Ph.D. 7
I Evelyn and Judy 11
II Cataracts in DS 36
III Other DS Patients 46
IV Other Retarded Patients 74
V Mental Retardation 94
VI "U" Series as Orthomolecular Therapy 96
VII Controversy 130
VIII The "U" Series 145
IX Historical Survey 161
X Non-medical Aspects 179
XI The Double-Blind Study 188
XII The FDA 209
"Doman-Delacato" Method, R. Doman, M.D. 233
s.,
Treatment of D. T. Kurita, M.D. 248
Comparison with Japanese Results 257
What Can Parents Do? 264
Conclusion 393
FIGURES
Treatment Chart 19
Evelyn 20-27
Judy 29-35
Larry 43-45
Oliver 48
Jimmy 49-52
David 56
Denece 57
Mark 58-59
Rachel 62
Jeanne 63-64
Dale 67
Brad 68-70
Alan 71
Gino 72
Normal Distribution of IQ Scores 73
vii
Wendy 78-80
Marcie 84-86
Ronna 88
Beth 90
Mary 92
Kent 102-105
"Clark" 111-115
NIH 134
NARC 137
"U" Series 143-144
Normal and Inborn Error Metabolism 160
Formation of the Trisomy 165
Mosaicism 166
Trisomy 168
Translocation 169
Translocation and Trisomy 176
Classification Chart 177
Genetic Variations 178
Word Rummy Cards 182-187
St. Rita 191, 193, 194
Changes in IQ Scores 258, 261, 263
PART II
DEAR WORLD 265
Dale 271
Nicholas 273
Steven 274
Daniel 275-281
Larry 282-287
David 288-292
Joseph 293-295
LeAnne 296-297
Jeanne 298-299
Suzanne 300
Byron 301-303
Victor 304
Susan 305-306
Marcello 307-309
Sara 31Q-316
Lisa 317-318
Dan 319-321
Stephanie 322-323
viii
Tom 324
Andy 325
Lee 326-330
Pam 331-336
Valerie 337-343
Karl 344-345
Carrie 346-348
Jimmy 349-352
Mariann 353-355
Craig 356-357
Liz 358-359
Greg 360-361
John 362-365
Philip 366-367
Natalie 368-369
Matthew 370
Rachel 371-373
Alex 374-376
Jacob 377-378
Carlene 379
Brad 380
Gino 381-392
\
ix
INTRODUCTION
It is proper that the medical profession
should be conservative. A physician who gave
his patients a drug that had not been carefully
tested may be guilty of an unethical action, in
that the side effects of the drug, over a long
period of time, might turn out to be so serious
as to neutralize completely any benefit
conferred on the patient by the drug. Even
after a new treatment has been shown to have
value, a rather long period of time, often ten
or twenty years, may be required before it is
accepted by the medical profession as a whole.
Thj.s problem of delay is especially acute
in the case of a treatment that does not promise
great financial benefit to some pharmaceutical
company or other part of our society. An
example is the delay of more than twenty years
in the acceptance of lithium therapy for
depression in the United States. Lithium salts
cannot be patented, and no one was willing to go
to the expense of getting FDA approval for the
drug. Another example is the use of EDTA
chelation therapy for the treatment of
atherosclerosis and other diseases. The company
that owned the United States rights to the EDTA
patent decided not to apply for FDA approval for
these uses, because of an economic study that
showed that the patent would expire before the
company would have been able to make a profit
from it.
There is a class of substances, called
orthomolecular substances normally present in
the human body, usually required for life. The
vitamins and minerals are good examples. There
is an increasingly great and increasingly
convincing body of evidence that the use of
vitamins, minerals, and other orthomolecular
substances in the proper amounts, the amounts
leading to optimum health and to the best
treatment of disease, has great value in the